A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine

• Published in: Clinical journal of gastroenterology Vol. 10; no. 6; pp. 551 - 557
• Main Authors: Hiyoshi, Masahide, Nanashima, Atsushi, Wada, Takashi, Tsuchimochi, Yuki, Hamada, Takeomi, Yano, Koichi, Imamura, Naoya, Fujii, Yoshiro
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.12.2017
• Subjects: Abdominal Surgery; Case Report; Colorectal Surgery; Gastroenterology; Hepatology; Medicine; Medicine & Public Health; Surgical Oncology; Conversion surgery; Gemcitabine; Nab-paclitaxel; Locally advanced pancreatic cancer; Curative resection
• ISSN: 1865-7257; 1865-7265
• DOI: 10.1007/s12328-017-0793-5

Pancreatic cancer patients have a poor prognosis because of a low rate of resection that results from distant metastases or local advancement. We report a successful case of unresectable locally advanced pancreatic cancer in a patient who was curatively resected after combination therapy with nab-paclitaxel (nab-PTX) and gemcitabine (GEM). A 61-year-old man was referred for treatment of a 45-mm pancreatic tail tumor involving the celiac axis, common hepatic artery, and splenic artery that appeared as an abnormal soft-density mass on imaging. This patient’s tumor was defined as unresectable due to local advancement, and, therefore, the powerful combined chemotherapy regimen of nab-PTX with GEM was initiated to allow for possible resection later. After three cycles of chemotherapy, a CT scan revealed that the soft-density mass around the celiac axis and common hepatic artery had dramatically disappeared, and the tumor was then determined to be a resectable lesion. Thus, distal pancreatectomy with en bloc celiac axis resection was performed and curability was achieved. There has been no tumor recurrence or distant metastasis at more than 12 months after surgery, and the patient remains alive at 17 months after initial chemotherapy.